Active immunization against serogroup B Neisseria meningitidis;La inmunización activa frente a Neisseria meningitidis serogrupo B

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 21, Issue 9, 2003, Pages 513-519

  Navarro Alonso, José Antonio ^a  

^a Direccion General de Salud Publica   (Spain)

Author keywords

Active immunization; Outer membrane proteins; Serogroup B meningococcus

Indexed keywords

ANTIBODY; ANTIGEN; BACTERIAL VACCINE; LIPOPOLYSACCHARIDE; OUTER MEMBRANE PROTEIN; POLYSACCHARIDE; PROTEIN; RECOMBINANT DNA; RECOMBINANT VACCINE;

ACTIVE IMMUNIZATION; ANTIGEN FUNCTION; BACTERIAL GENOME; BLOOD GROUP B; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; DRUG CONJUGATION; DRUG SCREENING; ELECTROPHORESIS; GENE SEQUENCE; GEOGRAPHY; HUMAN; IMMUNITY; MEMBRANE; MICROORGANISM; MORBIDITY; MORTALITY; NEISSERIA MENINGITIDIS; NONHUMAN; PREVALENCE; PROTEIN CONFORMATION; REVIEW; TECHNIQUE; VACCINATION;

EID: 0344872545     PISSN: 0213005X     EISSN: None     Source Type: Journal    
DOI: 10.1157/13052337     Document Type: Review

References (50)

1. Wyle F, Artenstein M, Brandt B, Tramont E, Kasper D, Alteiri P. Immunologic response of man to group B polysaccharide vaccines. J Infect Dis 1972;126:514-22.
2. Finne J, Leinonen M, Mäkelä P. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet 1983;2:355-7.
3. Mandrell R, Zollinger W. Measurement of antibodies to meningococcal group B polysaccharide: Low avidity binding and equilibrium binding constants. J Immunol 1982;129:2172-8.
4. Pollard A, Galasslni R, Roupe van der Voort E, Booy R, Langford P, Nadel S, et al. Humeral immune responses to Neisseria meningitidis in children. Infect Immun 1999;67:2441-51.
5. Swartley J, Marfin A, Edupuganti S, Liu L, Cieslak P, Perkins B, et al. Capsule switching of Neisseria meningitidis. Proc Natl Acad Sci USA 1997;94:271-6.
6. Herbert M, Heath P, Mayon-White R. Meningococcal vaccines for the United Kingdom. Communicable Disease Report 1995;5:R130-R134.
7. th Annual Meeting of IDSA. October 25-28, 2001. San Francisco, CA. Presentation number 368.
8. Wright J, Williams J, Christodoulides M, Heeckels J. Immunization with the recombinant PorB outer membrane protein induces a bactericidal immune response against Neisseria meningitidis. Infect Immun 2002;70:4028-34.
9. Lifely M, Roberts S, Shepperd W, Esdaille J, Wang S, Cleverly A, et al. Immunogenicity in adult males of a Neisseria meningitidis group B vaccine composed of polysaccharide complexed with outer membrane proteins. Vaccine 1991;9:60-6.
10. Ashton F, Ryan J, Michon F, Jennings H. Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide. Microbiol Pathog 1989;6:455-8.
11. Jennnings H, Roy R, Gamian A. Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J Immunol 1986;137:1708-10.
12. Fusco P, Michon F, Tai J, Blake M. Preclinical evaluation of a novel group B meningococcal conjugate vaccine that elicits bactericidal activity in both mice and nonhuman primates. J Infect Dis 1997;175:364-72.
13. Idanpaan I, Hoiby E, Chattopadhyay P, Airaksinen U, Michaelsen T, Wedege E. Antibodies to meningococcal class 1 outer-membrane protein and its variable regions in patients with systemic meningococcal disease. J Med Microbiol 1995:43:335-43.
14. Peeters C, Rümke H, Sundermann L, Rouppe van der Voort E, Meulenbelt J, Schuller M, et al. Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine. Vaccine 1996;14:1009-15.
15. Noronha C, Struchiner C, Halloran E. Assessment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: A case-control study. Int J Epidemiol 1995;24:1050-7.
16. Morley S, Cole M, Ison C, Camazara M, Sotolongo F, Anwar N, et al. Immunogenicity of a serogroup B meningococcal vaccine against multiple Neisseria meningitidis strains in infants. Pediatr Infect Dis J 2001;20:1054-61.
17. Sierra G. Group B meningococcal vaccines. International Conference on Emerging Infectious Diseases, 2002. Disponible en: http://www.cdc.gov/iceid.
18. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17 to 21, 2000. Washington, DC: American Society for Microbiology, 2000. Abstract 2087.
19. Cassio de Moraes J, Perkins B, Camargo M, Hidalgo N, Barbosa H, Tavares C, et al. Protective efficacy of a serogroup B meningococcal vaccine in Sao Paulo, Brazil. Lancet 1992;340:1074-8.
20. Boslego J, García J, Cruz C, Zollinger W, Brandt B, Ruiz S, et al. Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Vaccine 1995;13:821-9.
21. Bjune G, Hoiby E, Gronnesby J, Arnesen O, Frediksen J, Hlastenton A, et al. Effect of outer membrane vesicle vaccine against group B meningococcal disease in Norway. Lancet 1991;338:1093-6.
22. Fischer M, Carlone G, Holst J, Williams D, Stephens D, Perkins B. Neisseria meningitidis serogroup B outer membrane vesicle vaccine in adults with occupational risk for meningococcal disease. Vaccine 1999;17:2377-83.
23. Moxon R. Vacunación frente a Neisseria meningitidis serogrupo B: ¿un futuro esperanzador? En: Libro de Ponencias del I Congreso de la Asociación Española de Vacunelogía. Cadiz, 15 a 17 de noviembre de 2001. Asociación Española de Vacunelogía, 2001; p. 201-3.
24. Milagres L, Ramos S, Sacchi C, Melles C, Vieira V, Sato H, et al. Immune response of Brazilian children to a Neisseria meningitidis serogroup B outer membrane protein vaccine. Comparison with efficacy. Infect Immun 1994;62:4419-24.
25. Tappere J, Lagos R, Maldonado A, Plikaytis B, Williams D, Dykes J, et al. Immunogenicity of 2 serogroups B outer-membrane protein meningococcal vaccines. A randomized controlled trial in Chile. JAMA 1999;281:1520-7.
26. Wenger J. Serogroup B meningococcal disease. New outbreaks, new strategies. JAMA 1999;281:1541-3.
27. Katial R, Brandt B, Moran E, Marks S, Agnello V, Zollinger W. Immunogenicity and safety of a group B intranasal meningococcal native outer membrane vesicle vaccine. Infect Immun 2002;70:702-7.
28. Chiron Corporation and The National Institute of Public Health of Norway signing ceremony initiates meningitis vaccine development agreement. Disponible en: 〈 〈 httm: biz.yahoo.com/prnews/000525/cachiron.html〉.
29. Baker M, Martin D, Kieft C, Lennon D. A 10-year serogroup B meningococcal disease epidemic in New Zealand: Descriptive epidemiology, 1991-2000. J Paediatr Child Health 2001;37:13-9.
30. Jódar L, Feavers I, Salisbury D, Granoff D. Development of vaccines against meningococcal disease. Lancet 2002;359:1499-508.
31. Van der Ley P, Van der Biezen J, Poolman J. Construction of Neisseria meningitidis strains carrying multiple chromosomal copies of the PorA gene for use in the production of multivalent outer membrane vesicle vaccine. Vaccine 1995;13:401-7.
32. Cartwright K, Morris R, Rumke H, Fox A, Borrow R, Begg N. Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (Por A) outer membrane proteins. Vaccine 1999;17:2612-9.
33. De Kleijn E, De Groot R, Labadie J, Lafeber A, Van den Dobbelsteen G, Van Alphen L, et al. Immunogenicity and safety of a hexavalent meningococcal outer membrane-vesicle vaccine in children of 2-3 and 7-8 years of age. Vaccine 2000;18:1456-66.
34. Vermont C, Van Dijken H, De Groot R, Van den Dobbelsten G. Antibody avidity and IgG isotype distribution following immunisation with a monovalent meningococcal outer membrane vesicle (OMV) vaccine. En: Abstract book of the 19th Annual Meeting of the European Society for Pediatric Infectious Diseases. March 26-28, 2001, Istambul, Turkey, 2001; p. 39.
35. De Kleijn E, De Groot R, Lafeber A, Labadie J, Van Limpt C, Visser J, et al. Prevention of meningococcal serogroup B infections in children: A protein-based vaccine induces immunologic memory. J Infect Dis 2001;184:98-102.
36. Tondella M, Popovic T, Rosenstein N, Lake D, Carlone G, Mayer L, et al. Distribution of Neisseria meningitidis serogroup B serosubtypes and serotypes circulating in the United states. J Clin Microbiol 2000;38:3323-8.
37. Vázquez J. Enfermedad meningocócica y vacuna conjugada: Un largo, tortuoso y aún inacabado camino. Simposio: Vacunas conjugadas y nuevas oportunidades de prevención. Palma de Mallorca, 21-22 de Junio, 2002.
38. Morley S, Pollard A. Vaccine prevention of meningococcal disease, coming soon? Vaccine 2002;20:666-87.
39. Bos JM, Rümke HC, Welte R, Postma MJ, Jager JC. Health economics of a hexavalent meningococcal outer-membrane vesicle vaccine in children: Potential impact of introduction in the Dutch vaccination program. Vaccine 2002;20:202-7.
40. Wyeth Lederle Vaccines and the RIVM entre into exclusive collaboration to develop Pneumo/Mening combination vaccines. Disponible en: http://biz.yahoo.com/cnw/011106/pa_wyeth_ayerst_pharm_1.html
41. Sanchez S, Troncoso G, Criado M, Ferreirós C. In vitro induction of memory-driven responses against Neisseria menigitidis by priming with Neisseria lactamica. Vaccine 2002;20:2957-63.
42. Pintor M, Gómez JA, Ferón L, Ferreiros C, Criado M. Analysis of TbpA and TbpB functionality in defective mutants of Neisseria meningitidis. J Med Microbiol 1998;47:757-60.
43. Ferreirós C, Ferreiro N, Criado MT. Influencia de adyuvantes en la capacidad de los anticuerpos anti-Tbps de bloquear la unión de transferrina, la asimilación de hierro y el crecimiento en Neisseria meningitidis. Enferm Infecc Microbiol Clin 2002;20:313-6.
44. Vázquez JA. El desarrollo de vacunas frente a meningococo: Un largo, tortuoso y aùn inacabado camino. Enferm Infecc Microbiol Clin 2002;20:316-20.
45. Cadieux M, Plante M, Rioux C, Hamel J, Brodeur B, Martin D. Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immunol 1999;67:4955-9.
46. Rappuoli R. Conjugates and reverse vaccinology to eliminate bacterial meningitis. Vaccine 2001;19:2319-22.
47. Tettelin H, Saunders N, Heildeberg J, Jeffries A, Nelson K, Eisen J, et al. Complete genome sequence of Neisseria meningitidis serogroup B strain MC58. Science 2000;287:1809-15.
48. Sun Y, Bakshi S, Chalmers R, Tang C. Functional genomics of Neisseria meningitidis pathogenesis. Nat Med 2000;6:1269-73.
49. Neisseria lactamica as avaccine against meningococcal disease. Disponible en: http://www.meningitis-trust.org.uk/research3.htm. Accedido: 31 octubre 2002.
50. Tang C, Moxon R, Levine M. For discussion: Live attenuated vaccines for group B meningococcus. Vaccine 1999;17:114-7.